TabsDetailsBasic DetailsDate Posted: Wednesday, February 28, 2018Status: CompleteMedical Product: adalimumab, alemtuzumab, certolizumab, dalfampridine, dimethyl fumarate, etanercept, fingolimod, glatiramer acetate, golimumab, infliximab, interferon beta-1A, interferon beta-1B, mitoxantrone, natalizumab, pegylated interferon beta-1A, teriflunomide, ustekinumabDescription: This report contains estimates of the length of follow-up time for new users of immunosuppressive drugs (adalimumab, alemtuzumab, certolizumab, dalfampridine, dimethyl fumarate, etanercept, fingolimod, glatiramer acetate, golimumab, infliximab, interferon beta-1A, interferon beta-1B, mitoxantrone, natalizumab, pegylated intereferon beta-1A, teriflunomide, and ustekinumab) and for patients diagnosed with Crohn's disease, multiple sclerosis, psoriasis, and ulcerative colitis in the Sentinel Distributed Database (SDD). This report was distributed to Data Partners on June 30, 2017. Read More Deliverables (1)Sentinel Modular Program Report: Length of Follow-up Time for New Users of Immunosuppressive DrugsAdditional InformationAdditional DetailsFDA Center: CDERTime Period: January 1, 2000 - June 30, 2017Study Type: Modular ProgramAssessment Type: Exploratory AnalysesPopulation / Cohort: Individuals 18 years of age or olderData Sources: Sentinel Distributed Database (SDD)
